Dual inhibitions of soluble epoxide hydrolase (sEH) and cyclooxygenase-2 (COX-2), along with the GLP-1 analog liraglutide (LRG), activate the Sirt1/PI3K/AKT/mTOR and AMPK/mTOR/Beclin1 pathways to promote autophagy, alleviating NAFLD (148–150). Here, AKT1 is linked to metabolic dysfunction-associated steatotic liver disease.